

See “Seven days triple therapy for eradication of *Helicobacter pylori* does not alter the disease activity of patients with inflammatory bowel disease” on page 609-618.

**Supplementary Table 3.** Detailed Information of *Helicobacter pylori* Eradication of Patients in the Eradication Group

Characteristic		No. (%)
Diagnosis of infection	Serum anti- <i>H. pylori</i> IgG	65 (45.1)
	Urease breathing test	31 (21.5)
	Rapid urease test	22 (15.3)
	Histology	12 (8.3)
	Bacterial culture	4 (2.8)
	Fecal <i>H. pylori</i> antigen	2 (1.4)
	Unknown	8 (5.6)
Indication of eradication	Gastritis	97 (67.4)
	Peptic ulcer	37 (25.7)
	Gastric cancer	4 (2.8)
	Others, unknown	6 (4.2)
Regimen for eradication	First-line	123 (85.4)
	Second-line	21 (14.6)
Acid-suppressive drugs used at eradication	Lansoprazole	70 (48.6)
	Rabeprazole	39 (27.1)
	Esomeprazole	19 (13.2)
	Omeprazole	9 (6.3)
	Vonoprazan	5 (3.5)
	Unknown	2 (1.4)
Non-penicillin antibiotics used at eradication	Clarithromycin	120 (83.3)
	Metronidazole	22 (15.3)
	Unknown	2 (1.4)
Efficacy of eradication	Success	121 (84.0)
	Failure	22 (15.3)
	Unknown	1 (0.7)
Diagnosis of eradication	Urease breathing test	135 (93.8)
	Fecal <i>H. pylori</i> antigen	5 (3.5)
	Rapid urease test	1 (0.7)
	Bacterial culture	1 (0.7)
	Unknown	2 (1.4)

Values are presented as number (%).